Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B, for the quarter ended 30 June 2018 is posted.
View and download Appendix 4C quarterly report for the quarter ended 30 June 2018.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)